Biliary cystadenoma and cystadenocarcinoma laboratory findings
|
Biliary cystadenoma and cystadenocarcinoma Microchapters |
|
Differentiating Biliary cystadenoma and cystadenocarcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Biliary cystadenoma and cystadenocarcinoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Biliary cystadenoma and cystadenocarcinoma laboratory findings |
|
FDA on Biliary cystadenoma and cystadenocarcinoma laboratory findings |
|
CDC on Biliary cystadenoma and cystadenocarcinoma laboratory findings |
|
Biliary cystadenoma and cystadenocarcinoma laboratory findings in the news |
|
Blogs on Biliary cystadenoma and cystadenocarcinoma laboratory findings |
|
Directions to Hospitals Treating Biliary cystadenoma and cystadenocarcinoma |
|
Risk calculators and risk factors for Biliary cystadenoma and cystadenocarcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
Laboratory tests may show leukocytosis with a left shift in case of superinfection of the tumor. Elevation of alkaline phosphatase and bilirubin may be present. CA 19-9 may be elevated in the serum and in the cystic fluid, while CEA and α-fetoprotein levels are usually normal. Cystic fluid analysis during laparoscopy is advocated in the surgical treatment of hepatic cysts. In fact, the presence of elevated intracystic levels of CA 19-9 can support the diagnosis of cystadenoma.[1]
References